You've been by far the most realistic furthest out IDE submission forecaster here, and even that forecast looks very optimistic now. MK's repeated inability to focus and deliver to FDA what they need to green light Radiogel human trials greatly increases risk here. Sad, but that's the reality here.
Market Data 
Markets 
AI
